Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial
Open Access
Abstract
Introduction Treatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (MDR) LTBI are lacking. This trial aims to evaluate the efficacy of the antibiotic levofloxacin in preventing the development of active TB among latently infected contacts of index patients with MDR-TB. Methods and analysis A double-blind placebo-controlled parallel group randomised controlled trial will be conducted in 10 provinces of Vietnam. Household contacts living with patients with bacteriologically confirmed rifampicin-resistant or MDR-TB will be eligible for recruitment if they have a positive tuberculin skin test or are known to be immunosuppressed, and do not have active TB. Participants will be randomised to receive either levofloxacin or placebo tablets once per day for 6 months. Screening for incident TB will be performed at 6 months intervals. The primary study outcome is the incidence of bacteriologically confirmed TB within 30 months after randomisation. Analysis will be by intention to treat, using Poisson regression. Ethics Ethical approval from the University of Sydney Human Research Ethics Committee was obtained on 29 April 2015 (2014/929), and from the Vietnam Ministry of Health Institutional Review Board on 30 September 2015 (4040/QD-BYT). Dissemination Findings of the study will be published in peer-reviewed publications and conference presentations. Trial registration number ACTRN12616000215426.Keywords
This publication has 20 references indexed in Scilit:
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- Better than a Pound of Cure: Preventing the Development of Multidrug-Resistant TuberculosisFuture Microbiology, 2018
- Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2017
- Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious casesClinical Microbiology and Infection, 2017
- Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts: A Cost-Effectiveness AnalysisAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012The International Journal of Tuberculosis and Lung Disease, 2014
- Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort StudyClinical Infectious Diseases, 2013
- Treatment of latent tuberculosis infection: An updateRespirology, 2010
- Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2008
- SAMPLE SIZE REQUIREMENTS IN COHORT AND CASE-CONTROL STUDIES OF DISEASEAmerican Journal of Epidemiology, 1974